Genzyme Revenues Grow in First-Quarter 2011
- Details
- Category: Genzyme
Genzyme Corporation announced that its first-quarter 2011 revenue grew 7 percent compared with the same period in 2010. Genzyme first-quarter revenue grew to $1.009 billion from $941.9 million in the first quarter of 2010.
Shire delivers a strong first quarter performance
- Details
- Category: Shire
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces results for the three months to March 31, 2011.
Lilly and Medtronic Announce Drug-Device Collaboration for Parkinson's Disease
- Details
- Category: Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) and Medtronic, Inc. (NYSE: MDT) have entered into a collaboration to research and develop a new approach to treating Parkinson's disease that involves delivering a potential new medicine to the brain using an implantable drug delivery system.
Pfizer Comments on ORAL Sync Tofacitinib Data in EULAR Abstract LB0005
- Details
- Category: Pfizer
Pfizer Inc. commented on an abstract concerning the ORAL Sync Phase 3 study of tofacitinib in patients with rheumatoid arthritis (RA) which has been posted for the European League Against Rheumatism (EULAR) conference.
Bayer affirms the positive benefit-risk profile of its drospirenone- containing oral contraceptives
- Details
- Category: Bayer
Bayer HealthCare Pharmaceuticals is aware of two studies published in The British Medical Journal. These papers are "Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database" by Lianne Parkin et al (1); and
Lundbeck's partner Mochida receives approval of Lexapro in Japan
- Details
- Category: Lundbeck
H. Lundbeck A/S (Lundbeck) announced that Mochida Pharmaceutical Co., Ltd. (Mochida) has obtained approval of Lexapro® 10 mg (escitalopram) from the Japanese Ministry of Health, Labour and Welfare (MHLW).
Amgen and UCB Announce Positive Phase 2 Results of AMG 785/CDP7851
- Details
- Category: Amgen
Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) announced positive top-line results from their Phase 2 clinical study comparing sclerostin-antibody AMG 785/CDP7851 to placebo in postmenopausal women with low bone mineral density (BMD) for the treatment of postmenopausal osteoporosis (PMO).
More Pharma News ...
- Amgen's First Quarter 2011 Revenue Increased 3 Percent to $3.7 Billion
- Abbott Reports 17.4 Percent Sales Growth
- Novartis makes strong start for the year
- GSK welcomes key agreement to support global preparedness against pandemic influenza
- Roche Group's first-quarter 2011 sales on track for full-year targets
- Pfizer Announces Top-Line Results of Third Phase 3 Clinical Trial of Tofacitinib (CP-690,550)
- Bayer's Rivaroxaban Submitted for Approval in Japan